[go: up one dir, main page]

MX2017011182A - Analogos de amilina. - Google Patents

Analogos de amilina.

Info

Publication number
MX2017011182A
MX2017011182A MX2017011182A MX2017011182A MX2017011182A MX 2017011182 A MX2017011182 A MX 2017011182A MX 2017011182 A MX2017011182 A MX 2017011182A MX 2017011182 A MX2017011182 A MX 2017011182A MX 2017011182 A MX2017011182 A MX 2017011182A
Authority
MX
Mexico
Prior art keywords
analogues
amylin analogues
diseases
amylin
diabetes
Prior art date
Application number
MX2017011182A
Other languages
English (en)
Inventor
Dieter Wolfgang Hamprecht
Rasmus Just
Lise Giehm
Alexandrovna Deryabina Maria
Demmer Oliver
Sloth Villadsen Jesper
Skarbaliene Jolanta
Mosolff Mathiesen Jesper
Kofoed Munch Henrik
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017011182(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of MX2017011182A publication Critical patent/MX2017011182A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se refiere a análogos de amilina y a su uso en el tratamiento o la prevención de varias enfermedades, afecciones o trastornos, incluyendo obesidad, consumo excesivo de alimentos y enfermedades metabólicas asociadas tales como diabetes. Los análogos tienen una buena estabilidad física y química, una buena solubilidad y una larga duración de acción, y son adecuados para su uso en forma de una formulación líquida.
MX2017011182A 2015-03-18 2016-03-17 Analogos de amilina. MX2017011182A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15159737 2015-03-18
PCT/EP2016/055793 WO2016146739A1 (en) 2015-03-18 2016-03-17 Amylin analogues

Publications (1)

Publication Number Publication Date
MX2017011182A true MX2017011182A (es) 2018-06-06

Family

ID=52779493

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011182A MX2017011182A (es) 2015-03-18 2016-03-17 Analogos de amilina.

Country Status (19)

Country Link
US (2) US10766939B2 (es)
EP (1) EP3271381B1 (es)
JP (1) JP6769984B2 (es)
KR (1) KR20170126504A (es)
CN (1) CN107567459B (es)
AR (1) AR103954A1 (es)
AU (1) AU2016232218B2 (es)
BR (1) BR112017019378A2 (es)
CA (1) CA2979950A1 (es)
CL (1) CL2017002256A1 (es)
CO (1) CO2017008870A2 (es)
EA (1) EA035791B1 (es)
IL (1) IL253924A0 (es)
MX (1) MX2017011182A (es)
PE (1) PE20180497A1 (es)
PH (1) PH12017501674A1 (es)
SG (1) SG11201707286UA (es)
TW (1) TW201706294A (es)
WO (1) WO2016146739A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035791B1 (ru) 2015-03-18 2020-08-11 Зилэнд Фарма А/С Аналоги амилина
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
MX2021004185A (es) 2018-10-11 2021-09-08 Intarcia Therapeutics Inc Polipeptidos analogos de la amilina humana y sus metodos de uso.
JOP20220110A1 (ar) 2019-11-11 2023-01-30 Boehringer Ingelheim Int ناهضات مستقبل npy2
WO2021216586A1 (en) * 2020-04-20 2021-10-28 Intarcia Therapeutics, Inc. Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabetics
MX2023001532A (es) 2020-08-07 2023-03-08 Boehringer Ingelheim Int Agonistas del receptor npy2 solubles.
CN116322741A (zh) * 2020-09-24 2023-06-23 古布拉有限公司 具有改善的胰淀素受体(hAMY3R)效力的hAM15-52类似物
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
CN113893349B (zh) * 2021-12-13 2022-07-22 北京大学第三医院（北京大学第三临床医学院） 达格列净及其类似物在制备防治雄性生殖功能障碍的药物中的用途
KR20250017252A (ko) * 2022-05-27 2025-02-04 항저우 사이윈드 바이오사이언시즈 컴퍼니 리미티드 인간 아밀린 유사체 및 이의 유도체 및 이의 용도
TWI880227B (zh) * 2022-05-30 2025-04-11 丹麥商西蘭製藥公司 澱粉素類似物之液體調配物
WO2024022465A1 (zh) * 2022-07-29 2024-02-01 杭州九源基因工程有限公司 一种人胰淀素多肽衍生物及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
DK0567626T3 (da) * 1991-11-19 2001-12-17 Amylin Pharmaceuticals Inc Amylin-agonist-peptider og anvendelse deraf
AU7685894A (en) 1993-09-07 1995-03-27 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
UA72181C2 (uk) 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
US5677279A (en) 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
WO1999034764A2 (en) 1998-01-09 1999-07-15 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
BR0009040A (pt) 1999-03-17 2001-12-18 Novo Nordisk As Método para acilar um grupo amino de um peptìdeoou de uma proteìna, e, composto
WO2005000222A2 (en) 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
WO2006083254A1 (en) 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
DE102004051014A1 (de) 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
JP5252435B2 (ja) 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー／エス アミリン誘導体
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
EP2158214B1 (en) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
EP2340261B1 (en) 2008-10-21 2017-12-20 Novo Nordisk A/S Amylin derivatives
EA020596B1 (ru) 2008-12-15 2014-12-30 Зилэнд Фарма А/С Аналоги глюкагона
US8685919B2 (en) 2008-12-15 2014-04-01 Zealand Pharma A/S Glucagon analogues
US8642541B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
AU2008365556A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
US8748375B2 (en) 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
DK2454282T3 (en) 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
CN102639559B (zh) 2009-11-25 2015-04-29 诺沃—诺迪斯克有限公司 用于制备多肽的方法
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
KR20130086343A (ko) 2010-06-24 2013-08-01 질랜드 파마 에이/에스 글루카곤 유사체
ES2664509T3 (es) 2011-06-10 2018-04-19 Novo Nordisk A/S Derivados de pramlintida
SG11201403377QA (en) 2011-12-23 2014-07-30 Zealand Pharma As Glucagon analogues
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
WO2013156594A1 (en) * 2012-04-19 2013-10-24 Novo Nordisk A/S Human amylin analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
JP2016208556A (ja) * 2013-10-03 2016-12-08 三菱電機株式会社 デマンド予測装置及びデマンド予測方法
DK3137494T3 (da) 2014-05-02 2021-10-04 Univ New York State Res Found Isletamyloidpolypeptider med forbedret opløselighed
WO2016034604A1 (en) 2014-09-04 2016-03-10 Novo Nordisk A/S Novel amylin and calcitonin receptor agonist
EA035791B1 (ru) 2015-03-18 2020-08-11 Зилэнд Фарма А/С Аналоги амилина
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues

Also Published As

Publication number Publication date
EP3271381B1 (en) 2021-09-08
PH12017501674A1 (en) 2018-03-12
EA035791B1 (ru) 2020-08-11
BR112017019378A2 (pt) 2019-02-19
PE20180497A1 (es) 2018-03-09
AR103954A1 (es) 2017-06-14
EP3271381A1 (en) 2018-01-24
US20210115104A1 (en) 2021-04-22
AU2016232218B2 (en) 2020-09-10
US10766939B2 (en) 2020-09-08
EA201791617A1 (ru) 2018-02-28
CN107567459B (zh) 2021-09-24
SG11201707286UA (en) 2017-10-30
AU2016232218A1 (en) 2017-09-21
KR20170126504A (ko) 2017-11-17
IL253924A0 (en) 2017-10-31
CO2017008870A2 (es) 2017-11-10
CN107567459A (zh) 2018-01-09
US20160272693A1 (en) 2016-09-22
JP2018510871A (ja) 2018-04-19
CL2017002256A1 (es) 2018-04-02
CA2979950A1 (en) 2016-09-22
WO2016146739A1 (en) 2016-09-22
JP6769984B2 (ja) 2020-10-14
TW201706294A (zh) 2017-02-16

Similar Documents

Publication Publication Date Title
SA519401239B1 (ar) نظائر أميلين
PH12017501674A1 (en) Amylin analogues
JO3686B1 (ar) جلوكان ومركبات مساعِدات glp-1 مشتركة
WO2015101958A3 (en) Inhibitors of glutaminase
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
MX2014015423A (es) Analogos de peptido de exedina-4.
MX2015015249A (es) Peptidos terapeuticos.
PH12016501724A1 (en) Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
MX2016013029A (es) Compuestos de indanona sustituidos como modulares de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados.
MX376200B (es) Formulacion en polvo nasal para el tratamiento de hipoglicemia.
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
EP3102220C0 (en) SYNERGIC FOOD SUPPLEMENT COMPOSITIONS FOR THE PREVENTION, TREATMENT OR REGULATION OF INFLAMMATORY DISORDERS
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
MY175322A (en) Composition comprising okra for use in reducing dietary fat absorption
MX2019003725A (es) Glicinato de metformina, composiciones farmaceuticas que comprenden la misma, y metodos de uso de la misma.
PH12017500961A1 (en) Spice compositions and uses thereof
MX376191B (es) Composicion hiperosmolar de acido hialuronico.
HK1242712A1 (en) Amylin analogues
PL413830A1 (pl) Kompleks laktoferyny z jonami manganu, sposób jego otrzymywania, zastosowanie kompleksu oraz kompozycja farmaceutyczna zawierająca kompleks laktoferyny i jonów manganu
EP3226883C0 (en) COMPOSITIONS FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA